Endosane and UCI investigate the efficacy of new compounds for the treatment of PTSD
Endosane Pharmaceuticals and the University of California Irvine (UCI) have agreed to investigate the efficacy of two innovative compounds for the treatment of post-traumatic stress disorder (PTSD) through a series of preclinical studies. The studies will be conducted in the laboratory of the internationally renowned neuropharmacologist and leading endocannabinoid system researcher, Professor Daniele Piomelli. Results are expected as early as the first half of 2022.